Isomorphic Labs Owning Drug Candidates

This shift turns Isomorphic from a paid discovery vendor into a company that can own the most valuable step in drug creation, the medicine itself. Partnership work with Lilly and Novartis can bring in upfront fees and milestones, but the economics are capped and much of the upside sits with the pharma partner. Internal programs let Isomorphic keep the asset, decide when to license it, and capture far more value if a molecule reaches human proof of concept or approval.

• The company is building the org chart for that move. It raised $2.1B in May 2026, said it is advancing both partnered and wholly owned programs, and added a chief medical officer in Cambridge, Massachusetts to build clinical translation capability, which is the talent needed after molecule design and lab validation.
  3 isomorphiclabs 4 isomorphiclabs
• The current partnership model already shows the tradeoff. The Lilly and Novartis collaborations were announced as worth nearly $3B in potential payments excluding royalties, and Novartis expanded its scope in February 2025 from three targets to as many as six. That is meaningful non dilutive funding, but the lead commercial economics still sit downstream with the pharma owner.
  1 isomorphiclabs 2 isomorphiclabs
• Other AI drug companies are moving the same direction. Genesis is explicitly using wholly owned oncology and immunology programs to retain more downstream economics, while Xaira was built from the start as an internal engine to generate data, models, and medicines rather than sell software. The category is converging on biotech style ownership, not tools revenue.
  5 sacra 6 sacra

The next phase is whether Isomorphic can turn model quality into named development candidates and then early human data. If that happens, valuation will be driven less by partnership headlines and more by pipeline value, because a single credible internal asset can reset the company from AI collaborator to AI native drug maker.